Supernus Reports Q4 Revenue of $211.6M, Beating Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy SUPN?
Reports Q4 revenue $211.6M, consensus $195.16M. "We made significant progress in 2025 against our strategic objectives, with record total revenues, including strong growth in combined revenues of our growth products, the successful acquisition of Sage Therapeutics, Inc., and the U.S. Food and Drug Administration's approval and launch of ONAPGO for Parkinson's disease," said Jack Khattar, President and CEO of Supernus. "In 2026, we are focused on continued progress of our key growth products, including resumption of new patient initiation for ONAPGO, while advancing our pipeline of promising therapeutic candidates."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUPN
Wall Street analysts forecast SUPN stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 55.090
Low
55.00
Averages
61.33
High
65.00
Current: 55.090
Low
55.00
Averages
61.33
High
65.00
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Supernus Pharmaceuticals Reports Q4 2025 Results and 2026 Guidance
- Revenue Growth: In Q4 2025, Supernus reported total revenue of $211.6 million, a 21% increase from $174.2 million in Q4 2024, indicating strong market acceptance of newer therapies despite declines in legacy product sales.
- Increased Operating Loss: The company faced an operating loss of $3.9 million in Q4 2025, a stark contrast to operating earnings of $21.4 million in Q4 2024, primarily due to rising SG&A acquisition-related costs, highlighting financial pressures during expansion.
- Annual Performance Review: For the full year 2025, total revenues reached $719 million, up 9%, but the operating loss widened to $62.3 million, impacted by $72.9 million in acquisition costs related to Sage Therapeutics, reflecting short-term financial challenges from its acquisition strategy.
- 2026 Outlook: Supernus projects total revenues of $840 million to $870 million for 2026, with operating earnings expected to rebound to between $0 million and $30 million, indicating confidence in future market performance despite ongoing adjustments in profitability.
See More
Supernus Pharmaceuticals Reports Record Q4 2025 Earnings and Strategic Progress
- Record Revenue: Supernus Pharmaceuticals achieved total revenue of $211.6 million in Q4 2025, a 21% increase year-over-year, with net product sales reaching $158.1 million, indicating robust performance in core products, particularly Qelbree and GOCOVRI.
- Significant Product Growth: The four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—accounted for approximately 76% of total revenue in Q4, with ONAPGO's net sales rising from $6.8 million in Q3 to $8.9 million, reflecting strong market demand and resolution of supply issues.
- Optimistic Outlook: Management projects total revenues for 2026 to range from $840 million to $870 million, with ONAPGO net sales expected between $45 million and $70 million, demonstrating confidence in future growth while maintaining a strong cash flow and debt-free financial position.
- R&D and Integration Focus: Supernus completed the acquisition of Sage Therapeutics and plans to retain some assets for internal development, emphasizing the company's strategic priority on R&D and product portfolio integration to drive long-term growth.
See More
Supernus Pharmaceuticals Reports Strong Q4 2025 Earnings and Revenue Growth
- Significant Revenue Growth: Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, reflecting a 21.5% year-over-year increase and surpassing the market expectation of $196.69 million, indicating strong market performance.
- Earnings Per Share Beat: The EPS for the quarter was $0.92, up 22.7% from $0.75 a year ago, and significantly exceeding the consensus estimate of $0.28, showcasing a notable improvement in the company's profitability.
- Positive Market Reaction: With both revenue and EPS exceeding expectations, investor sentiment towards Supernus is optimistic, likely driving stock price appreciation and reflecting confidence in the company's continued growth potential.
- Key Metrics Insight: Analysts emphasize that while revenue and earnings are focal points for investors, the performance of other key metrics provides deeper insights into the company's future stock price trajectory, aiding investors in making more informed decisions.
See More
Supernus Pharmaceuticals Q4 2025 Earnings Exceed Expectations
- Strong Earnings Report: Supernus Pharmaceuticals reported a Q4 2025 GAAP EPS of $0.07, beating expectations by $0.28, which highlights the company's significant improvement in profitability and boosts market confidence in its future growth prospects.
- Revenue Growth: The company achieved revenue of $211.6 million in Q4, representing a 21.5% year-over-year increase and exceeding market expectations by $16.44 million, indicating robust product demand and continued market share expansion.
- Adjusted Operating Earnings: For Q4 2025, adjusted operating earnings were $48.5 million, slightly up from $48.3 million in the same period of 2024, demonstrating the company's success in cost control and efficiency improvements.
- Cash Flow Status: As of December 31, 2025, Supernus had approximately $308.7 million in cash and cash equivalents, down from $453.6 million in 2024, primarily due to funding the Sage acquisition, although cash generated from operations partially offset this decline.
See More
Supernus Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Schedule: Supernus Pharmaceuticals will participate in several investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit, showcasing its advancements in CNS disease treatments, which is expected to attract investor interest and enhance company visibility.
- Conference Dates and Locations: The TD Cowen conference is set for March 2 at 2:30 PM in Boston, while the Jefferies summit will take place on March 10 in Miami Beach; additionally, the Barclays Global Healthcare Conference is scheduled for March 11, further expanding the company's engagement opportunities with investors.
- Live Webcast and Replays: The company will provide live audio webcasts of the TD Cowen and Barclays conference presentations on its website, with archived replays available for 60 days post-conference, ensuring that investors who cannot attend live can access critical information, thereby enhancing investor relations management.
- Product Portfolio and Market Outlook: Supernus focuses on developing treatments for various CNS disorders, including ADHD, and with growing market demand, the company is poised to achieve revenue growth through ongoing R&D and marketing efforts, thereby strengthening its competitive position in the biopharmaceutical industry.
See More
Supernus Pharmaceuticals Q4 Earnings Announcement Scheduled
- Earnings Release Date: Supernus Pharmaceuticals (SUPN) is set to announce its Q4 2023 earnings on February 24th after market close, with consensus EPS estimated at $0.28 and revenue projected at $195.16 million, reflecting a 12% year-over-year growth.
- Performance Prediction Analysis: Over the past year, SUPN has not beaten EPS estimates at all, while it has successfully met revenue estimates 75% of the time, indicating a strong performance in revenue generation and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates experienced three upward revisions and one downward, showcasing analysts' differing views on the company's future performance amid market fluctuations.
- Market Outlook: The outlook for Supernus Pharmaceuticals in 2026 is viewed positively, with a maintained “Buy” rating, indicating analysts' confidence in the company's long-term growth potential, particularly in the ongoing investment and innovation within the CNS therapeutics sector.
See More
Supernus Pharmaceuticals Reports Q4 2025 Results and 2026 Guidance
- Revenue Growth: In Q4 2025, Supernus reported total revenue of $211.6 million, a 21% increase from $174.2 million in Q4 2024, indicating strong market acceptance of newer therapies despite declines in legacy product sales.
- Increased Operating Loss: The company faced an operating loss of $3.9 million in Q4 2025, a stark contrast to operating earnings of $21.4 million in Q4 2024, primarily due to rising SG&A acquisition-related costs, highlighting financial pressures during expansion.
- Annual Performance Review: For the full year 2025, total revenues reached $719 million, up 9%, but the operating loss widened to $62.3 million, impacted by $72.9 million in acquisition costs related to Sage Therapeutics, reflecting short-term financial challenges from its acquisition strategy.
- 2026 Outlook: Supernus projects total revenues of $840 million to $870 million for 2026, with operating earnings expected to rebound to between $0 million and $30 million, indicating confidence in future market performance despite ongoing adjustments in profitability.
See More
Supernus Pharmaceuticals Reports Record Q4 2025 Earnings and Strategic Progress
- Record Revenue: Supernus Pharmaceuticals achieved total revenue of $211.6 million in Q4 2025, a 21% increase year-over-year, with net product sales reaching $158.1 million, indicating robust performance in core products, particularly Qelbree and GOCOVRI.
- Significant Product Growth: The four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—accounted for approximately 76% of total revenue in Q4, with ONAPGO's net sales rising from $6.8 million in Q3 to $8.9 million, reflecting strong market demand and resolution of supply issues.
- Optimistic Outlook: Management projects total revenues for 2026 to range from $840 million to $870 million, with ONAPGO net sales expected between $45 million and $70 million, demonstrating confidence in future growth while maintaining a strong cash flow and debt-free financial position.
- R&D and Integration Focus: Supernus completed the acquisition of Sage Therapeutics and plans to retain some assets for internal development, emphasizing the company's strategic priority on R&D and product portfolio integration to drive long-term growth.
See More
Supernus Pharmaceuticals Reports Strong Q4 2025 Earnings and Revenue Growth
- Significant Revenue Growth: Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, reflecting a 21.5% year-over-year increase and surpassing the market expectation of $196.69 million, indicating strong market performance.
- Earnings Per Share Beat: The EPS for the quarter was $0.92, up 22.7% from $0.75 a year ago, and significantly exceeding the consensus estimate of $0.28, showcasing a notable improvement in the company's profitability.
- Positive Market Reaction: With both revenue and EPS exceeding expectations, investor sentiment towards Supernus is optimistic, likely driving stock price appreciation and reflecting confidence in the company's continued growth potential.
- Key Metrics Insight: Analysts emphasize that while revenue and earnings are focal points for investors, the performance of other key metrics provides deeper insights into the company's future stock price trajectory, aiding investors in making more informed decisions.
See More
Supernus Pharmaceuticals Q4 2025 Earnings Exceed Expectations
- Strong Earnings Report: Supernus Pharmaceuticals reported a Q4 2025 GAAP EPS of $0.07, beating expectations by $0.28, which highlights the company's significant improvement in profitability and boosts market confidence in its future growth prospects.
- Revenue Growth: The company achieved revenue of $211.6 million in Q4, representing a 21.5% year-over-year increase and exceeding market expectations by $16.44 million, indicating robust product demand and continued market share expansion.
- Adjusted Operating Earnings: For Q4 2025, adjusted operating earnings were $48.5 million, slightly up from $48.3 million in the same period of 2024, demonstrating the company's success in cost control and efficiency improvements.
- Cash Flow Status: As of December 31, 2025, Supernus had approximately $308.7 million in cash and cash equivalents, down from $453.6 million in 2024, primarily due to funding the Sage acquisition, although cash generated from operations partially offset this decline.
See More
Supernus Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Schedule: Supernus Pharmaceuticals will participate in several investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit, showcasing its advancements in CNS disease treatments, which is expected to attract investor interest and enhance company visibility.
- Conference Dates and Locations: The TD Cowen conference is set for March 2 at 2:30 PM in Boston, while the Jefferies summit will take place on March 10 in Miami Beach; additionally, the Barclays Global Healthcare Conference is scheduled for March 11, further expanding the company's engagement opportunities with investors.
- Live Webcast and Replays: The company will provide live audio webcasts of the TD Cowen and Barclays conference presentations on its website, with archived replays available for 60 days post-conference, ensuring that investors who cannot attend live can access critical information, thereby enhancing investor relations management.
- Product Portfolio and Market Outlook: Supernus focuses on developing treatments for various CNS disorders, including ADHD, and with growing market demand, the company is poised to achieve revenue growth through ongoing R&D and marketing efforts, thereby strengthening its competitive position in the biopharmaceutical industry.
See More
Supernus Pharmaceuticals Q4 Earnings Announcement Scheduled
- Earnings Release Date: Supernus Pharmaceuticals (SUPN) is set to announce its Q4 2023 earnings on February 24th after market close, with consensus EPS estimated at $0.28 and revenue projected at $195.16 million, reflecting a 12% year-over-year growth.
- Performance Prediction Analysis: Over the past year, SUPN has not beaten EPS estimates at all, while it has successfully met revenue estimates 75% of the time, indicating a strong performance in revenue generation and market confidence.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates experienced three upward revisions and one downward, showcasing analysts' differing views on the company's future performance amid market fluctuations.
- Market Outlook: The outlook for Supernus Pharmaceuticals in 2026 is viewed positively, with a maintained “Buy” rating, indicating analysts' confidence in the company's long-term growth potential, particularly in the ongoing investment and innovation within the CNS therapeutics sector.
See More
